IP Library › Granted Patent US 7,019,193
Granted Patent B2
US 7,019,193 · App. 10/188,658 · Granted Mar 28, 2006

Treatments using transgenic goat produced antithrombin III

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,019,193
App. No.
10/188,658
Granted
Mar 28, 2006
Kind
B2
Abstract

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Claims (12)

1. A method of treating a subject having an ATIII deficiency or inflammation, comprising:

administering to the subject goat mammary gland produced antithrombin III having a monosaccharide composition which comprises a higher level of mannose than plasma derived antithrombin III, wherein thrombin is inhibited.

2. The method of claim 1 , wherein the mammary gland produced antithrombin III further has a monosaccharide composition which comprises fucose.

3. The method of claim 1 , wherein the mammary gland produced antithrombin III further has a monosaccharide composition which comprises GalNAc.

4. The method of claim 1 , wherein the mammary gland produced antithrombin III is produced in the mammary glands of a transgenic goat.

5. The method of claim 1 , wherein the ATIII deficiency is hereditary ATIII deficiency.

6. The method of claim 1 , wherein the ATIII deficiency is acquired ATIII deficiency.

7. A method of treating inflammation in a subject, comprising:

administering to the subject a Moat mammary gland produced antithrombin III having a monosaccharide composition which comprises a higher level of mannose than plasma derived antithrombin III, wherein thrombin is inhibited.

8. The method of claim 7 , wherein the mammary gland produced antithrombin III further has a monosaccharide composition which comprises fucose.

9. The method of claim 7 , wherein the mammary gland produced antithrombin III further has a monosaccharide composition which comprises GaINAc.

10. The method of claim 7 , wherein the mammary gland produced antithrombin III is produced in the mammary glands of a transgenic goat.

Assignments (5)
CHANGE OF NAME Recorded Jul 18, 2013
From: GTC BIOTHERAPEUTICS, INC.
To: REVO BIOLOGICS, INC.
Reel/Frame 030831/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2010
From: LUNDBECK INC.
To: GTC BIOTHERAPEUTICS, INC.
Reel/Frame 024936/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2010
From: DITULLIO, PAUL; MEADE, HARRY; COLE, EDWARD S.
To: GENZYME TRANSGENIC CORPORATION
Reel/Frame 024937/0270 →
CHANGE OF NAME Recorded Sep 1, 2009
From: OVATION PHARMACEUTICALS, INC
To: LUNDBECK INC.
Reel/Frame 023163/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2008
From: GTC BIOTHERAPEUTICS, INC.
To: OVATION PHARMACEUTICALS, INC.
Reel/Frame 021411/0334 →